宁婉斌
About 宁婉斌
宁婉斌 is a CRA II at 百时美施贵宝 in 上海市 and also works at Jiangsu Hengrui Medicine Co., Ltd. as a CRA.
Professional Title
宁婉斌 holds the title of CRA II, reflecting her advanced role in clinical research and trial management. She currently occupies this position at two organizations: 百时美施贵宝, a global biopharmaceutical company, and Jiangsu Hengrui Medicine Co., Ltd., a prominent local pharmaceutical firm. Her dual roles demonstrate her capabilities in managing clinical trials across both multinational and local contexts.
Current Employment
宁婉斌 is currently employed as a CRA II at 百时美施贵宝, located in 上海市,中国. She started this position in April 2021. Additionally, she works in a similar capacity at Jiangsu Hengrui Medicine Co., Ltd., one of the leading pharmaceutical companies in China. Her roles involve the monitoring and management of clinical trials to ensure compliance with regulatory and ethical standards.
Educational Background
宁婉斌 completed her undergraduate education at 重庆医科大学, where she studied 临床药学 and obtained a bachelor's degree. Her academic tenure lasted from 2013 to 2018, totaling five years. This education provided a solid foundation in clinical pharmacy, preparing her for various professional responsibilities in the pharmaceutical industry.
Industry Experience
宁婉斌 has substantial experience working in the pharmaceutical industry. She has been involved in clinical research and trial management within both multinational corporations like 百时美施贵宝 and local companies such as Jiangsu Hengrui Medicine Co., Ltd. Her experience underscores her ability to navigate the regulatory landscapes and operational differences between global and domestic pharmaceutical firms.
Location and Professional Environment
Based in 杨浦区, 上海市, 宁婉斌 is situated in a key hub for medical and pharmaceutical research in China. This location provides her with significant opportunities for professional growth and collaboration within the industry. 杨浦区's status as a research hub facilitates access to comprehensive resources, professional networks, and institutional support critical to her roles as a CRA II.